
  
    
      
        
        Angiogenesis_NNP is_VBZ the_DT growth_NN of_IN blood_NN vessels_NNS from_IN a_DT
        pre-existing_JJ vessel_NN bed_NN ._. Clinical_NNP interest_NN in_IN the_DT control_NN
        of_IN angiogenesis_NNS arises_VBZ from_IN two_CD distinct_JJ quarters_NNS ._. In_IN one_CD
        case_NN ,_, the_DT goal_NN is_VBZ to_TO block_VB the_DT growth_NN of_IN new_JJ vessels_NNS as_IN a_DT
        means_NN to_TO suppress_VB and_CC /_NN or_CC regress_NNS tumor_NN growth_NN ,_, or_CC to_TO
        suppress_VB vessel_NN proliferation_NN in_IN pathologies_NNS such_JJ as_IN
        diabetes_NN ._. In_IN the_DT second_JJ case_NN ,_, the_DT objective_NN is_VBZ to_TO induce_VB or_CC
        stimulate_VB vessel_NN growth_NN in_IN patients_NNS with_IN conditions_NNS
        characterized_VBN by_IN insufficient_JJ blood_NN flow_NN ,_, such_JJ as_IN ischemic_JJ
        heart_NN disease_NN and_CC peripheral_JJ vascular_NN diseases_NNS ._. The_DT latter_JJ
        applications_NNS are_VBP the_DT focus_NN of_IN this_DT review_NN ._. We_PRP discuss_VBP some_DT
        of_IN the_DT recent_JJ efforts_NNS to_TO induce_VB new_JJ vessel_NN growth_NN and_CC we_PRP
        highlight_VB challenges_NNS that_WDT have_VBP arisen_VBN regarding_VBG the_DT means_NNS
        of_IN delivery_NN and_CC efficacy_NN of_IN angiogenesis_NNS induction_NN ._.
      
      
        Angiogenic_NNP stimuli_NNS
        
          Fibroblast_NNP growth_NN factor_NN
          The_DT fibroblast_NN growth_NN factor_NN (_( FGF_NNP )_) family_NN consists_VBZ of_IN
          an_DT ever-increasing_JJ number_NN of_IN peptide_NN growth_NN factors_NNS with_IN
          diverse_JJ cellular_JJ targets_NNS and_CC biological_JJ effects_NNS [_NN 1_CD ]_NN ._. Two_CD
          family_NN members_NNS ,_, acidic_JJ fibroblast_NN growth_NN factor_NN (_( FGF-_NNP 1_LS )_)
          and_CC FGF-_NNP 2_CD ,_, have_VBP a_DT strong_JJ affinity_NN for_IN heparin_NN and_CC have_VBP
          been_VBN studied_VBN for_IN their_PRP$ effects_NNS on_IN vascular_NN cells_NNS ,_,
          including_VBG endothelial_NN cells_NNS and_CC smooth_JJ muscle_NN cells_NNS ._.
          Extensive_NNP evidence_NN indicates_VBZ that_IN both_DT FGF-_NNP 1_CD and_CC FGF-_NNP 2_CD
          are_VBP potent_JJ angiogenic_JJ factors_NNS ,_, providing_VBG support_NN for_IN
          their_PRP$ use_NN as_IN stimuli_NNS for_IN therapeutic_JJ angiogenesis_NNS 
          in_IN vivo_NN ._. It_PRP is_VBZ also_RB important_JJ to_TO
          note_VB that_IN many_JJ cell_NN types_NNS express_VBP one_CD of_IN the_DT four_CD FGF_NNP
          receptors_NNS ,_, and_CC that_IN FGF_NNP has_VBZ been_VBN shown_VBN to_TO have_VB biological_JJ
          effects_NNS in_IN a_DT number_NN of_IN cell_NN systems_NNS including_VBG induction_NN
          of_IN neurite_NN outgrowth_NN ,_, suppression_NN of_IN skeletal_NN muscle_NN
          differentiation_NN ,_, induction_NN of_IN bone_NN formation_NN and_CC
          neuroprotection_NN ,_, to_TO name_VB just_RB a_DT few_JJ ._.
        
        
          Vascular_NNP endothelial_NN growth_NN factor-_NN A_DT
          VEGF-A_NNP is_VBZ the_DT prototypic_JJ member_NN of_IN a_DT family_NN of_IN
          secreted_JJ ,_, homodimeric_JJ glycoproteins_NNS with_IN endothelial_NN
          cell-specific_JJ mitogenic_JJ activity_NN and_CC the_DT ability_NN to_TO
          stimulate_VB angiogenesis_NNS 
          in_IN vivo_NN [_NN 2_CD ]_NN ._. VEGF-A_NNP also_RB increases_VBZ
          vascular_NN permeability_NN ,_, with_IN an_DT effect_NN 10_CD ,_, 000_CD times_NNS more_RBR
          potent_JJ than_IN that_DT of_IN the_DT vasoactive_JJ substance_NN histamine_NN ;_:
          VEGF-A_NNP was_VBD originally_RB purified_JJ based_VBN on_IN this_DT property_NN ,_,
          and_CC was_VBD named_VBN vascular_NN permeability_NN factor_NN [_NN 3_CD ]_NN ._. The_DT
          VEGF-A_NNP family_NN of_IN polypeptides_NNS consists_VBZ of_IN a_DT number_NN of_IN
          biochemically_RB distinct_JJ isoforms_NNS (_( three_CD isoforms_NNS in_IN the_DT
          mouse_NN and_CC up_IN to_TO five_CD in_IN humans_NNS )_) that_WDT are_VBP generated_VBN
          through_IN alternative_JJ mRNA_NN splicing_VBG of_IN a_DT single_JJ gene_NN [_NN 4_CD ,_,
          5_CD ]_NN ._. The_DT isoforms_NNS are_VBP named_VBN by_IN the_DT number_NN of_IN amino_JJ acids_NNS
          that_WDT comprise_VBP the_DT proteins_NNS ;_: the_DT human_JJ isoforms_NNS include_VBP
          VEGF_NNP 121_CD ,_, VEGF_NNP 145_CD ,_, VEGF_NNP 165_CD ,_, VEGF_NNP 189_CD ,_, and_CC VEGF_NNP 206_CD ._.
        
      
      
        Preclinical_NNP studies_NNS
        Current_JJ clinical_JJ trials_NNS of_IN angiogenesis_NNS factors_NNS were_VBD
        preceded_VBN by_IN a_DT large_JJ number_NN of_IN studies_NNS using_VBG animal_NN models_NNS
        of_IN cardiac_JJ or_CC peripheral_JJ ischemia_NN ._. Early_RB studies_VBZ involved_VBD
        protein_NN administration_NN ,_, whereas_IN later_JJ efforts_NNS began_VBD to_TO
        employ_VB gene_NN therapy_NN ._. In_IN one_CD early_JJ study_NN using_VBG recombinant_JJ
        protein_NN ,_, a_DT single_JJ intra-arterial_JJ injection_NN of_IN 500_CD -_: 1000_CD μg_NN
        VEGF_NNP 165_CD into_IN rabbits_NNS with_IN severe_JJ experimental_JJ hind_NN limb_NN
        ischemia_NN increased_VBD collateral_NN vessels_NNS ,_, as_IN detected_VBN by_IN
        angiography_NN and_CC histological_JJ analysis_NN [_NN 6_CD ]_NN ._. Naked_NNP plasmid_NN
        DNA_NNP injected_VBD directly_RB into_IN the_DT skeletal_NN muscle_NN in_IN a_DT later_JJ
        study_NN ,_, using_VBG the_DT same_JJ hind_NN limb_NN ischemia_NN model_NN ,_, also_RB
        yielded_VBD increased_VBN collateral_NN vessels_NNS ,_, as_IN determined_VBN by_IN
        angiography_NN and_CC improved_VBN perfusion_NN [_NN 7_CD ]_NN ._.
        Although_IN such_JJ reports_NNS of_IN increased_VBN vessel_NN growth_NN and_CC
        functional_JJ improvement_NN in_IN response_NN to_TO exogenously_RB
        administered_VBN angiogenic_JJ factors_NNS are_VBP encouraging_VBG ,_, it_PRP is_VBZ
        essential_JJ to_TO note_VB that_IN animal_NN models_NNS such_JJ as_IN the_DT ischemic_JJ
        hind_NN limb_NN model_NN have_VBP definite_JJ limitations_NNS ._. Whereas_IN the_DT
        ischemia_NN in_IN the_DT animal_NN models_NNS is_VBZ acute_JJ (_( produced_VBN by_IN
        surgical_JJ procedure_NN )_) ,_, the_DT ischemia_NN that_WDT characterizes_VBZ the_DT
        human_JJ disease_NN often_RB arises_VBZ over_IN an_DT extended_VBN time_NN and_CC occurs_VBZ
        in_IN the_DT context_NN of_IN complex_JJ atherosclerotic_JJ processes_NNS ._. The_DT
        responses_NNS seen_VBN in_IN the_DT experimental_JJ models_NNS may_MD thus_RB be_VB quite_RB
        different_JJ in_IN terms_NNS of_IN the_DT kinetics_NNS of_IN vessel_NN growth_NN as_RB well_RB
        as_IN the_DT nature_NN of_IN the_DT resultant_JJ vessels_NNS ._.
        In_IN a_DT study_NN assessing_VBG the_DT effects_NNS of_IN VEGF-A_NNP on_IN myocardial_NN
        ischemia_NN in_IN a_DT porcine_NN model_NN of_IN progressive_JJ coronary_JJ artery_NN
        occlusion_NN ,_, VEGF-A_NNP was_VBD delivered_VBN by_IN osmotic_JJ pump_NN and_CC
        magnetic_JJ resonance_NN mapping_NN revealed_VBD a_DT reduction_NN in_IN the_DT size_NN
        of_IN the_DT ischemic_JJ zone_NN and_CC improved_VBN cardiac_JJ function_NN [_NN 8_CD ]_NN ._. A_DT
        single_JJ bolus_JJ injection_NN was_VBD also_RB found_VBN to_TO produce_VB
        significant_JJ improvements_NNS in_IN myocardial_NN blood_NN flow_NN and_CC
        function_NN [_NN 9_CD ]_NN ._. Myocardial_NNP ischemia_NN in_IN animals_NNS has_VBZ also_RB been_VBN
        treated_VBN with_IN FGF_NNP ._. Delivery_NN of_IN FGF-_NNP 2_CD via_IN implantation_NN of_IN
        heparin-alginate_JJ beads_NNS led_VBN to_TO an_DT 80_CD %_NN reduction_NN in_IN infarct_NN
        size_NN and_CC improved_VBN cardiac_JJ function_NN in_IN pigs_NNS with_IN
        experimentally_RB induced_VBN coronary_JJ artery_NN constrictions_NNS ,_, as_IN
        compared_VBN with_IN untreated_JJ controls_NNS [_NN 10_CD ]_NN ._. These_DT studies_NNS were_VBD
        followed_VBN closely_RB by_IN the_DT demonstration_NN of_IN gene_NN therapy_NN in_IN a_DT
        porcine_NN model_NN of_IN stress-induced_JJ myocardial_NN ischemia_NN ._.
        Intracoronary_NNP injection_NN of_IN a_DT recombinant_JJ adenovirus_JJ
        expressing_VBG another_DT member_NN of_IN the_DT FGF_NNP family_NN ,_, human_JJ FGF-_NNP 5_CD ,_,
        led_VBN to_TO improvements_NNS in_IN stress-induced_JJ function_NN and_CC blood_NN
        flow_NN that_WDT were_VBD maintained_VBN for_IN 12_CD weeks_NNS [_NN 11_CD ]_NN ._.
      
      
        Clinical_NNP trials_NNS
        
          Fibroblast_NNP growth_NN factor_NN
          In_IN one_CD study_NN ,_, human_JJ recombinant_JJ FGF-_NNP 2_CD was_VBD administered_VBN
          intraoperatively_RB to_TO areas_NNS of_IN the_DT coronary_JJ artery_NN in_IN 20_CD
          patients_NNS who_WP were_VBD undergoing_VBG surgical_JJ revascularization_NN [_NN
          14_CD ]_NN ._. Angiographic_NNP analysis_NN revealed_VBD evidence_NN of_IN
          collateralization_NN ._. Local_JJ sustained_VBN release_NN of_IN high_JJ dose_NN
          (_( but_CC not_RB low_JJ dose_NN )_) FGF-_NNP 2_CD to_TO ischemic_JJ areas_NNS ,_, in_IN 24_CD
          patients_NNS during_IN bypass_NN surgery_NN ,_, led_VBN to_TO a_DT reduction_NN in_IN
          stress_NN defect_NN size_NN [_NN 15_CD ]_NN ._. In_IN a_DT recent_JJ study_NN involving_VBG 59_CD
          patients_NNS with_IN coronary_JJ disease_NN ,_, the_DT response_NN to_TO
          intravenous_JJ or_CC intracoronary_JJ human_JJ recombinant_JJ FGF-_NNP 2_CD was_VBD
          monitored_VBN by_IN single_JJ photon_NN emission_NN computed_JJ tomography_NN
          (_( SPECT_NNP )_) imaging_NN [_NN 16_CD ]_NN ._. Perfusion_NNP was_VBD monitored_VBN at_IN
          approximately_RB 1_CD ,_, 2_CD ,_, and_CC 3_CD months_NNS after_IN growth_NN factor_NN
          administration_NN ._. Analysis_NNP of_IN global_JJ stress_NN perfusion_NN or_CC
          inducible_JJ ischemia_NN revealed_VBD a_DT consistent_JJ and_CC sustained_VBN
          reduction_NN in_IN the_DT extent_NN and_CC severity_NN of_IN stress-inducible_JJ
          ischemia_NN ,_, as_RB well_RB as_IN an_DT improvement_NN in_IN resting_VBG perfusion_NN
          in_IN areas_NNS where_WRB there_EX was_VBD a_DT risk_NN of_IN ischemia_NN ._.
        
        
          Vascular_NNP endothelial_NN growth_NN factor_NN
          In_IN an_DT early_JJ phase_NN I_PRP trial_NN to_TO test_VB the_DT safety_NN and_CC
          bioactivity_NN of_IN VEGF-A_NNP ,_, naked_JJ VEGF_NNP 165_CD DNA_NNP was_VBD injected_VBN
          into_IN the_DT myocardium_NN of_IN five_CD patients_NNS who_WP had_VBD failed_VBN
          standard_JJ therapy_NN ._. SPECT_NNP imaging_NN demonstrated_VBN reduced_VBN
          ischemia_NN [_NN 17_CD ]_NN ._. Adenoviral_NNP delivery_NN of_IN VEGF_NNP 121_CD to_TO the_DT
          myocardium_NN of_IN 21_CD patients_NNS by_IN direct_JJ injection_NN ,_, either_CC as_IN
          an_DT adjunct_NN to_TO coronary_JJ bypass_NN grafting_VBG or_CC as_IN the_DT sole_JJ
          therapy_NN ,_, led_VBN to_TO improvement_NN in_IN the_DT area_NN injected_VBD ,_, as_IN
          measured_VBN by_IN angiography_NN ;_: angina_NN was_VBD also_RB reduced_VBN [_NN 18_CD ]_NN ._.
          Administration_NNP of_IN recombinant_JJ VEGF_NNP 121_CD improved_VBN function_NN ,_,
          as_IN detected_VBN by_IN SPECT_NNP [_NN 19_CD ]_NN ._. Furthermore_RB ,_, this_DT study_NN
          revealed_VBD a_DT dose-dependent_JJ improvement_NN in_IN both_DT stress_NN
          perfusion_NN and_CC rest_NN perfusion_NN ;_: there_EX was_VBD an_DT infrequent_JJ
          response_NN in_IN patients_NNS who_WP received_VBD low_JJ dose_NN VEGF_NNP and_CC an_DT
          improvement_NN in_IN five_CD out_IN of_IN six_CD patients_NNS who_WP received_VBD high_JJ
          dose_NN VEGF_NNP ._. In_IN a_DT different_JJ approach_NN ,_, VEGF_NNP cDNA_NN was_VBD
          delivered_VBN via_IN liposomes_NNS by_IN catheter_NN to_TO coronary_JJ arteries_NNS
          following_VBG angioplasty_NN [_NN 20_CD ]_NN ._. While_IN this_DT phase_NN I_PRP safety_NN
          trial_NN did_VBD not_RB show_VB an_DT effect_NN of_IN VEGF-A_NNP on_IN the_DT degree_NN of_IN
          coronary_JJ ischemia_NN ,_, it_PRP did_VBD prove_VB that_IN the_DT treatment_NN was_VBD
          well_RB tolerated_JJ ._.
          It_PRP is_VBZ important_JJ to_TO note_VB that_IN no_DT phase_NN II_NNP controlled_VBD
          studies_NNS using_VBG defined_VBN and_CC quantifiable_JJ endpoints_NNS have_VBP
          demonstrated_VBN efficacy_NN of_IN therapeutic_JJ angiogenesis_NNS ._. This_DT
          highlights_VBZ the_DT main_JJ obstacles_NNS for_IN assessing_VBG a_DT therapeutic_JJ
          response_NN to_TO angiogenesis_NNS therapy_NN ,_, the_DT reliability_NN of_IN the_DT
          assessment_NN methods_NNS and_CC the_DT possible_JJ complications_NNS of_IN the_DT
          placebo_NN effect_NN ._. There_EX is_VBZ thus_RB a_DT critical_JJ need_NN for_IN more_RBR
          controlled_JJ trials_NNS and_CC for_IN the_DT development_NN of_IN better_JJR
          defined_VBN and_CC more_RBR quantifiable_JJ endpoints_NNS ._.
        
      
      
        Modes_NNP of_IN delivery_NN
        
          Protein_NNP therapy_NN
          At_IN present_JJ ,_, the_DT administration_NN of_IN protein_NN seems_VBZ to_TO be_VB
          preferable_JJ to_TO gene_NN therapy_NN [_NN 12_CD ]_NN ._. This_DT is_VBZ mainly_RB because_IN
          dosage_NN modulation_NN in_IN most_JJS clinical_JJ settings_NNS is_VBZ far_RB easier_JJR
          with_IN purified_JJ protein_NN than_IN with_IN gene_NN therapy_NN ,_, which_WDT is_VBZ
          hampered_VBN by_IN the_DT lack_NN of_IN a_DT regulable_JJ expression_NN vector_NN ._.
          Although_IN protein_NN therapy_NN has_VBZ many_JJ advantages_NNS ,_, there_EX are_VBP
          nevertheless_RB technical_JJ problems_NNS associated_VBN with_IN protein_NN
          administration_NN ,_, including_VBG optimization_NN of_IN purification_NN
          and_CC formulation_NN of_IN delivery_NN for_IN single_NN and_CC /_NN or_CC multiple_JJ
          angiogenic_JJ factors_NNS ._.
          Recent_JJ advances_NNS in_IN drug_NN delivery_NN methods_NNS using_VBG
          bioerodible_JJ polymer_NN matrices_NNS will_MD allow_VB long-term_RB
          sustained_VBN release_NN of_IN the_DT growth_NN factors_NNS [_NN 24_CD ]_NN ._. This_DT will_MD
          resolve_VB one_CD of_IN the_DT major_JJ problems_NNS associated_VBN with_IN protein_NN
          administration_NN ;_: namely_RB ,_, the_DT limited_JJ tissue_NN half-life_NN of_IN
          the_DT purified_JJ angiogenic_JJ factors_NNS in_IN patients_NNS ._. An_DT important_JJ
          consideration_NN ,_, however_RB ,_, is_VBZ that_DT protein_NN therapy_NN is_VBZ
          limited_VBN to_TO secreted_JJ factors_NNS ._. Delivery_NN of_IN intracellular_NN
          modulators_NNS for_IN therapeutic_JJ angiogenesis_NNS ,_, including_VBG
          transcription_NN factors_NNS that_WDT control_NN angiogenesis_NNS such_JJ as_IN
          hypoxia_NN inducible_JJ factor-_NN 1_CD alpha_NN (_( HIF-_NNP 1_CD α_NN )_) ,_, is_VBZ only_RB
          possible_JJ through_IN gene_NN therapy_NN ._.
        
        
          Gene_NNP therapy_NN
          Viral_NNP vectors_NNS have_VBP been_VBN the_DT most_RBS commonly_RB used_VBN means_NNS
          of_IN gene_NN delivery_NN for_IN both_DT VEGF-A_NNP and_CC FGF-_NNP 2_CD ._. Gene_NNP therapy_NN
          presents_VBZ an_DT attractive_JJ alternative_NN to_TO purified_JJ proteins_NNS
          because_IN it_PRP offers_VBZ the_DT possibility_NN of_IN sustained_VBN production_NN
          of_IN one_CD or_CC more_JJR factors_NNS following_VBG a_DT single_JJ administration_NN ._.
          Furthermore_RB ,_, tissue-specific_JJ and_CC highly_RB localized_JJ
          production_NN of_IN the_DT therapeutic_JJ factor_NN is_VBZ possible_JJ ,_, through_IN
          the_DT use_NN of_IN tissue-specific_JJ promoters_NNS ._.
          However_RB ,_, a_DT variety_NN of_IN issues_NNS have_VBP implications_NNS for_IN the_DT
          use_NN of_IN viral_JJ vectors_NNS in_IN gene_NN therapy_NN ._. Obvious_NNP potential_JJ
          concerns_NNS are_VBP the_DT immune_JJ and_CC inflammatory_JJ responses_NNS to_TO
          viral_JJ vectors_NNS ._. Patients_NNS who_WP received_VBD VEGF_NNP 121_CD via_IN an_DT
          adenoviral_NN vector_NN had_VBD increased_VBN levels_NNS of_IN serum_NN
          anti-adenoviral_JJ neutralizing_VBG antibodies_NNS ,_, but_CC there_EX was_VBD no_DT
          report_NN on_IN an_DT inflammatory_JJ response_NN in_IN these_DT patients_NNS [_NN
          19_CD ]_NN ._. The_DT use_NN of_IN adenovirus-mediated_JJ gene_NN therapy_NN in_IN
          treating_VBG brain_NN tumors_NNS has_VBZ been_VBN reported_VBN to_TO lead_VB to_TO active_JJ
          brain_NN inflammation_NN as_RB well_RB as_IN persistent_JJ (_( up_IN to_TO 3_CD months_NNS
          after_IN treatment_NN )_) transgene_NN expression_NN [_NN 25_CD ]_NN ._.
          The_DT lack_NN of_IN regulable_JJ gene_NN expression_NN is_VBZ another_DT
          potential_JJ barrier_NN ._. Some_DT systems_NNS for_IN inducible_JJ gene_NN
          expressions_NNS have_VBP proved_VBN to_TO be_VB effective_JJ and_CC safe_JJ in_IN
          animal_NN models_NNS [_NN 26_CD ]_NN ,_, but_CC have_VBP not_RB yet_RB been_VBN tested_VBN in_IN
          humans_NNS ._. Recent_JJ advances_NNS in_IN stem_NN cell_NN research_NN provide_VBP the_DT
          possibility_NN of_IN combining_VBG gene_NN therapy_NN with_IN 
          ex_FW vivo_NN gene_NN transfer_NN into_IN stem_NN
          cells_NNS for_IN angiogenesis_NNS therapy_NN ,_, as_IN will_MD be_VB discussed_VBN
          later_RB ._. If_IN successful_JJ ,_, this_DT approach_NN may_MD overcome_VB most_JJS of_IN
          the_DT obstacles_NNS presented_VBN by_IN gene_NN therapy_NN ._.
        
      
      
        Considerations_NNP for_IN the_DT future_JJ
        
          Interpatient_NNP variability_NN
          It_PRP is_VBZ not_RB clear_JJ why_WRB some_DT individuals_NNS develop_VBP a_DT
          collateral_NN circulation_NN sufficient_JJ to_TO compensate_VB for_IN their_PRP$
          ischemic_JJ vascular_NN disease_NN whereas_IN others_NNS do_VBP not_RB ._.
          Certainly_RB ,_, features_NNS such_JJ as_IN the_DT extent_NN of_IN the_DT disease_NN and_CC
          the_DT time_NN frame_NN over_IN which_WDT the_DT ischemia_NN develops_VBZ are_VBP
          contributing_VBG factors_NNS ._. However_RB ,_, other_JJ previously_RB
          unconsidered_JJ variables_NNS appear_VBP to_TO play_VB important_JJ
          roles_NNS ._.
          Collateral_NNP vessel_NN development_NN ,_, as_IN measured_VBN by_IN blood_NN
          pressure_NN ,_, angiography_NN ,_, and_CC vessel_NN density_NN ,_, was_VBD
          significantly_RB reduced_VBN in_IN old_JJ (_( 4_CD -_: 5_CD years_NNS old_JJ )_) versus_CC young_JJ
          (_( 6_CD -_: 8_CD months_NNS old_JJ )_) animals_NNS [_NN 27_CD ]_NN ,_, in_IN a_DT rabbit_NN model_NN of_IN hind_NN
          limb_NN ischemia_NN ._. Endothelial_NNP cell_NN dysfunction_NN and_CC reduced_VBN
          VEGF-A_NNP levels_NNS were_VBD the_DT reasons_NNS suggested_VBD for_IN the_DT reduced_VBN
          collateral_NN response_NN ._. A_DT subsequent_JJ study_NN ,_, demonstrating_VBG an_DT
          age-dependent_JJ reduction_NN in_IN HIF-_NNP 1_CD α_NN activity_NN ,_, provides_VBZ one_CD
          explanation_NN for_IN the_DT lower_JJR VEGF-A_NNP expression_NN in_IN response_NN
          to_TO hypoxia_NN in_IN aged_VBN animals_NNS [_NN 28_CD ]_NN ._. A_DT reduced_VBN response_NN to_TO
          hypoxia_NN might_MD translate_VB into_IN a_DT weaker_JJR angiogenic_JJ
          response_NN ._. This_DT is_VBZ supported_VBN by_IN the_DT fact_NN that_IN the_DT extent_NN
          of_IN hypoxic_JJ induction_NN of_IN VEGF-A_NNP in_IN monocytes_NNS correlates_NNS
          strongly_RB with_IN the_DT presence_NN of_IN collateral_NN vessels_NNS in_IN
          patients_NNS [_NN 29_CD ]_NN ._.
          It_PRP is_VBZ possible_JJ that_IN genetic_JJ variability_NN may_MD also_RB play_VB
          a_DT significant_JJ role_NN in_IN an_DT individual_NN 's_POS ability_NN to_TO generate_VB
          collateral_NN vessels_NNS in_IN response_NN to_TO ischemia_NN ,_, as_RB well_RB as_IN
          their_PRP$ capacity_NN to_TO respond_VB to_TO an_DT exogenous_JJ angiogenic_JJ
          agent_NN ._. Not_RB surprisingly_RB ,_, a_DT recent_JJ report_NN that_WDT assessed_VBD
          the_DT angiogenic_JJ response_NN in_IN a_DT murine_NN corneal_JJ pocket_NN model_NN
          to_TO a_DT fixed_VBN dosage_NN of_IN FGF-_NNP 2_CD in_IN various_JJ strains_NNS of_IN mice_NNS
          suggested_VBD that_IN genetic_JJ backgrounds_NNS may_MD influence_VB
          angiogenic_JJ response_NN [_NN 30_CD ]_NN ._. A_DT nearly_RB 10_CD -_: fold_VB range_NN of_IN
          response_NN to_TO the_DT fixed_VBN dosage_NN of_IN FGF-_NNP 2_CD was_VBD observed_VBN among_IN
          different_JJ inbred_JJ strains_NNS of_IN mice_NNS ,_, suggesting_VBG that_IN genetic_JJ
          variability_NN may_MD indeed_RB play_VB a_DT significant_JJ role_NN in_IN
          determining_VBG the_DT magnitude_NN of_IN angiogenic_JJ response_NN to_TO
          FGF-_NNP 2_CD ._.
        
        
          Systemic_NNP effects_NNS
          If_IN VEGF-A_NNP delivery_NN leads_VBZ to_TO significant_JJ circulating_VBG
          levels_NNS ,_, as_IN has_VBZ been_VBN observed_VBN following_VBG myocardial_NN
          transfection_NN with_IN VEGF-A_NNP cDNA_NN [_NN 31_CD ]_NN ,_, then_RB it_PRP may_MD possibly_RB
          affect_VB angiogenesis_NNS elsewhere_RB [_NN 32_CD ]_NN ._. As_IN plaque_NN
          progression_NN might_MD be_VB dependent_JJ on_IN angiogenesis_NNS [_NN 33_CD ]_NN ,_,
          investigators_NNS were_VBD prompted_VBN to_TO examine_VB the_DT effect_NN of_IN
          VEGF-A_NNP administration_NN on_IN this_DT process_NN ._. Mice_NNS that_WDT were_VBD
          double_JJ deficient_NN in_IN apolipoprotein_NN E_NNP and_CC apolipoprotein_NN β_NN
          100_CD were_VBD treated_VBN with_IN a_DT single_JJ intraperitoneal_NN injection_NN
          of_IN VEGF_NNP 165_CD recombinant_JJ human_JJ protein_NN (_( 2_CD μg_NN /_NN kg_NN )_) ._. This_DT led_VBN
          to_TO significant_JJ increases_NNS in_IN plaque_NN area_NN compared_VBN with_IN
          untreated_JJ controls_NNS [_NN 34_CD ]_NN ._. In_IN contrast_NN ,_, there_EX has_VBZ been_VBN no_DT
          evidence_NN of_IN disease_NN progression_NN ,_, to_TO date_NN ,_, in_IN 42_CD patients_NNS
          treated_VBN with_IN intra-arterial_JJ gene_NN transfer_NN of_IN naked_JJ VEGF-A_NNP
          cDNA_NN ._. This_DT has_VBZ been_VBN delivered_VBN either_CC to_TO promote_VB
          therapeutic_JJ angiogenesis_NNS (_( 12_CD patients_NNS )_) or_CC to_TO accelerate_VB
          re-endothelization_JJ (_( 30_CD patients_NNS )_) [_NN 35_CD ]_NN ._. Although_IN these_DT
          observations_NNS suggest_VBP that_IN human_JJ sensitivity_NN to_TO VEGF-A_NNP may_MD
          be_VB lower_JJR than_IN in_IN animal_NN models_NNS ,_, it_PRP will_MD be_VB necessary_JJ to_TO
          study_VB a_DT larger_JJR cohort_NN of_IN patients_NNS ,_, with_IN appropriate_JJ
          controls_NNS ,_, over_IN a_DT longer_JJR time_NN period_NN to_TO confirm_VB this_DT [_NN
          36_CD ]_NN ._.
          VEGF_NNP has_VBZ also_RB been_VBN shown_VBN to_TO mediate_VB the_DT vessel_NN growth_NN
          that_WDT characterizes_VBZ tumor_NN expansion_NN as_RB well_RB as_IN the_DT
          neovascularization_NN that_WDT is_VBZ associated_VBN with_IN diabetic_JJ
          retinopathy_NN ._. Although_IN VEGF_NNP is_VBZ produced_VBN locally_RB in_IN both_DT of_IN
          these_DT circumstances_NNS ,_, it_PRP is_VBZ not_RB known_VBN whether_IN systemic_JJ
          administration_NN of_IN the_DT factor_NN could_MD exacerbate_VB these_DT
          conditions_NNS by_IN further_JJ stimulating_VBG vessel_NN growth_NN ._.
          Selection_NN of_IN the_DT patient_NN population_NN that_WDT may_MD benefit_VB from_IN
          angiogenic_JJ therapy_NN may_MD thus_RB have_VB to_TO involve_VB screening_NN for_IN
          coexisting_VBG conditions_NNS that_WDT could_MD be_VB activated_VBN or_CC worsened_VBN
          by_IN exposure_NN to_TO proangiogenic_JJ agents_NNS ._.
          VEGF-A_NNP ,_, FGF-_NNP 1_CD ,_, and_CC FGF-_NNP 2_CD have_VBP all_DT demonstrated_VBN
          systemic_JJ vascular_NN effects_NNS ._. FGF-_NNP 1_CD and_CC FGF-_NNP 2_CD have_VBP been_VBN
          shown_VBN to_TO reduce_VB blood_NN pressure_NN in_IN a_DT dose-dependent_JJ manner_NN
          in_IN rats_NNS [_NN 37_CD ]_NN ._. Similarly_RB ,_, VEGF-A_NNP has_VBZ been_VBN reported_VBN to_TO
          cause_VB hypotension_NN and_CC death_NN in_IN pigs_NNS following_VBG an_DT
          intracoronary_JJ bolus_JJ administration_NN [_NN 38_CD ]_NN ._. Subsequent_JJ
          studies_NNS have_VBP revealed_VBN that_IN VEGF-A_NNP administration_NN causes_NNS
          greater_JJR vasodilatation_NN of_IN coronary_JJ vessels_NNS than_IN serotonin_NN
          or_CC nitroglycerin_NN ,_, and_CC also_RB causes_VBZ tachyphylaxis_NNS via_IN a_DT
          nitric_JJ oxide-dependent_JJ mechanism_NN [_NN 39_CD ]_NN ._. VEGF-A_NNP
          administration_NN to_TO the_DT extremities_NNS of_IN patients_NNS has_VBZ also_RB
          been_VBN associated_VBN with_IN hypotension_NN and_CC edema_NN [_NN 40_CD ]_NN ._. These_DT
          side_NN effects_NNS can_MD be_VB partly_RB explained_VBN by_IN the_DT fact_NN that_IN
          VEGF-A_NNP is_VBZ a_DT potent_JJ vascular_NN permeability_NN factor_NN ._.
        
        
          VEGF-A_NNP isoforms_NNS in_IN angiogenesis_NNS therapy_NN
          The_DT five_CD VEGF-A_NNP protein_NN isoforms_NNS in_IN humans_NNS (_( and_CC at_IN
          least_JJS three_CD major_JJ isoforms_NNS in_IN the_DT mouse_NN )_) have_VBP different_JJ
          biochemical_JJ and_CC biological_JJ properties_NNS [_NN 41_CD ]_NN ._. It_PRP is_VBZ
          therefore_RB important_JJ to_TO determine_VB whether_IN different_JJ VEGF-A_NNP
          isoforms_NNS give_VBP rise_NN to_TO different_JJ quality_NN or_CC quantity_NN of_IN
          vessels_NNS ._. Expression_NNP of_IN the_DT various_JJ isoforms_NNS during_IN
          development_NN is_VBZ modulated_JJ both_DT spatially_RB and_CC temporally_RB [_NN
          42_CD ]_NN ,_, and_CC observations_NNS from_IN gene_NN knockout_NN studies_NNS have_VBP
          proven_VBN that_IN these_DT isoforms_NNS do_VBP not_RB have_VB equivalent_NN
          biological_JJ functions_NNS during_IN vessel_NN development_NN [_NN 42_CD ,_, 43_CD ]_NN ._.
          Furthermore_RB ,_, there_EX is_VBZ considerable_JJ variability_NN in_IN the_DT
          phenotype_NN of_IN vessels_NNS in_IN tumors_NNS expressing_VBG different_JJ
          isoforms_NNS [_NN 44_CD ]_NN ._. For_IN example_NN ,_, vessels_NNS within_IN tumors_NNS
          expressing_VBG predominantly_RB the_DT VEGF_NNP 189_CD isoform_NN ,_, which_WDT has_VBZ a_DT
          strong_JJ heparin-binding_JJ affinity_NN and_CC thus_RB is_VBZ highly_RB
          localized_JJ ,_, are_VBP much_RB less_RBR leaky_JJ than_IN the_DT vessels_NNS in_IN tumors_NNS
          expressing_VBG the_DT more_RBR diffusible_JJ VEGF_NNP 165_CD and_CC VEGF_NNP 121_CD
          isoforms_NNS [_NN 45_CD ]_NN ._. It_PRP will_MD be_VB interesting_JJ and_CC important_JJ to_TO
          determine_VB whether_IN these_DT observations_NNS from_IN experimental_JJ
          systems_NNS can_MD help_VB predict_VB the_DT results_NNS of_IN clinical_JJ trials_NNS ,_,
          which_WDT primarily_RB employ_VB the_DT VEGF_NNP 165_CD isoform_NN ._. Finally_RB ,_,
          since_IN multiple_JJ VEGF-A_NNP isoforms_NNS are_VBP expressed_VBN during_IN
          vascular_NN development_NN [_NN 42_CD ]_NN ,_, it_PRP will_MD also_RB be_VB important_JJ to_TO
          determine_VB whether_IN the_DT use_NN of_IN multiple_JJ isoforms_NNS in_IN
          angiogenesis_NNS therapy_NN will_MD be_VB necessary_JJ to_TO replicate_VB 
          in_IN vivo_NN conditions_NNS ._.
        
      
      
        Achieving_NNP vessel_NN stability_NN
        The_DT induction_NN of_IN new_JJ vessels_NNS to_TO supply_VB ischemic_JJ tissues_NNS
        is_VBZ the_DT primary_JJ goal_NN of_IN angiogenic_JJ therapy_NN ._. Reaching_VBG this_DT
        objective_NN is_VBZ ,_, however_RB ,_, highly_RB complex_JJ ._. Vessels_NNP formed_VBD in_IN
        response_NN to_TO artificial_JJ angiogenic_JJ stimuli_NNS are_VBP prone_JJ to_TO
        regression_NN unless_IN they_PRP are_VBP remodeled_VBN into_IN mature_VBP ,_, stable_JJ
        vessels_NNS [_NN 46_CD ]_NN ._. Thus_RB ,_, as_IN the_DT level_NN of_IN knowledge_NN regarding_VBG
        the_DT mechanisms_NNS of_IN vessel_NN growth_NN and_CC stabilization_NN
        increases_NNS ,_, there_EX is_VBZ increasing_VBG concern_NN that_IN the_DT simple_JJ
        application_NN of_IN a_DT bolus_JJ of_IN angiogenic_JJ factor_NN may_MD be_VB
        insufficient_JJ for_IN stable_JJ vessel_NN formation_NN ,_, or_CC may_MD even_RB be_VB
        dangerous_JJ ._.
        Early_RB studies_VBZ involving_VBG the_DT administration_NN of_IN VEGF-A_NNP
        showed_VBD angiographic_JJ evidence_NN of_IN new_JJ vessel_NN formation_NN ,_, but_CC
        these_DT vessels_NNS did_VBD not_RB persist_VB and_CC they_PRP regressed_JJ within_IN 3_CD
        months_NNS [_NN 40_CD ]_NN ._. It_PRP was_VBD recently_RB reported_VBN that_IN continuous_JJ
        delivery_NN of_IN VEGF-A_NNP into_IN murine_NN hearts_NNS by_IN retroviral_NN
        transfer_NN led_VBN to_TO the_DT formation_NN of_IN aberrant_NN vessels_NNS and_CC
        hemangioma-like_JJ structures_NNS [_NN 23_CD ]_NN ._. One_CD of_IN the_DT major_JJ problems_NNS
        encountered_VBD in_IN the_DT use_NN of_IN VEGF-A_NNP is_VBZ that_IN vessels_NNS formed_VBN are_VBP
        unstable_JJ and_CC leaky_JJ [_NN 47_CD ]_NN ._. It_PRP has_VBZ been_VBN speculated_VBN that_IN
        VEGF-A_NNP alone_RB may_MD not_RB be_VB sufficient_JJ to_TO form_VB stable_JJ ,_, mature_VBP
        vessels_NNS that_WDT are_VBP characterized_VBN by_IN the_DT recruitment_NN of_IN the_DT
        perivascular_NN mural_NN cells_NNS ,_, such_JJ as_IN pericytes_NNS or_CC smooth_JJ
        muscle_NN cells_NNS [_NN 48_CD ]_NN ._. This_DT process_NN of_IN vessel_NN maturation_NN is_VBZ
        called_VBN arteriogenesis_NNS and_CC is_VBZ arguably_RB the_DT ideal_JJ way_NN to_TO form_VB
        stable_JJ vessels_NNS for_IN therapeutic_JJ purposes_NNS [_NN 49_CD ]_NN ._.
      
      
        Administration_NNP of_IN multiple_JJ factors_NNS
        Various_JJ growth_NN factors_NNS such_JJ as_IN angiopoietin_NN (_( ang_NN )_) -_: 1_CD ,_,
        platelet-derived_JJ growth_NN factor_NN ,_, transforming_VBG growth_NN
        factor-β_JJ as_IN well_RB as_IN VEGF-A_NNP are_VBP also_RB involved_VBN in_IN
        arteriogenesis_NNS ,_, and_CC it_PRP may_MD therefore_RB be_VB necessary_JJ to_TO use_VB
        combinations_NNS of_IN these_DT factors_NNS to_TO obtain_VB stable_JJ and_CC mature_VBP
        vessels_NNS (_( Fig_NNP ._. 1_LS )_) ._. Indeed_RB ,_, when_WRB VEGF-A_NNP and_CC ang-_NN 1_CD are_VBP
        administered_VBN together_RB in_IN animal_NN models_NNS ,_, the_DT resulting_VBG
        vessels_NNS are_VBP much_RB more_RBR stable_JJ and_CC less_RBR leaky_JJ than_IN those_DT that_WDT
        are_VBP induced_VBN by_IN VEGF-A_NNP alone_RB [_NN 50_CD ]_NN ._. Similarly_RB ,_,
        administration_NN of_IN submaximal_NN doses_NNS of_IN ang-_NN 1_CD and_CC VEGF-A_NNP in_IN a_DT
        rabbit_NN ischemic_JJ hind_NN limb_NN model_NN led_VBN to_TO a_DT stronger_JJR effect_NN on_IN
        resting_VBG and_CC maximal_NN blood_NN flow_NN and_CC capillary_JJ formation_NN than_IN
        either_DT of_IN the_DT agents_NNS alone_RB [_NN 51_CD ]_NN ._.
      
      
        Using_VBG a_DT master_NN switch_NN gene_NN
        Another_DT approach_NN that_IN addresses_VBZ the_DT involvement_NN of_IN
        multiple_JJ factors_NNS in_IN therapeutic_JJ angiogenesis_NNS is_VBZ the_DT use_NN of_IN
        a_DT so-called_JJ '_POS master_NN switch_NN gene_NN '_'' of_IN angiogenesis_NNS ,_, such_JJ as_IN
        HIF-_NNP 1_CD α_NN [_NN 52_CD ]_NN ._. This_DT transcription_NN factor_NN can_MD activate_VBP a_DT
        collection_NN of_IN different_JJ genes_NNS that_WDT are_VBP involved_VBN in_IN
        angiogenesis_NNS ,_, including_VBG those_DT encoding_VBG VEGF-A_NNP ,_, VEGF_NNP
        receptor_NN 1_CD (_( Flt-_NNP 1_LS )_) ,_, and_CC ang-_NN 2_CD [_NN 53_CD ,_, 54_CD ]_NN ._. It_PRP is_VBZ hoped_VBN that_IN
        using_VBG a_NNP '_POS master_NN switch_NN gene_NN '_'' will_MD result_VB in_IN more_JJR stable_JJ
        vessels_NNS ,_, because_IN the_DT processes_NNS by_IN which_WDT they_PRP are_VBP formed_VBN
        would_MD resemble_VB more_RBR closely_RB those_DT of_IN normal_JJ vessel_NN
        development_NN ._.
      
      
        Stem_NNP cells_NNS in_IN therapeutic_JJ angiogenesis_NNS
        The_DT existence_NN of_IN circulating_VBG endothelial_NN precursor_NN (_( CEP_NNP )_)
        cells_NNS in_IN adults_NNS has_VBZ been_VBN reported_VBN [_NN 55_CD ,_, 56_CD ]_NN ._. It_PRP has_VBZ also_RB
        been_VBN demonstrated_VBN that_IN similar_JJ precursor_NN cells_NNS may_MD give_VB
        rise_NN to_TO both_DT endothelial_NN cells_NNS and_CC perivascular_NN mural_NN cells_NNS
        [_NN 57_CD ]_NN ._. Furthermore_RB ,_, in_IN an_DT 
        in_IN vitro_NN model_NN of_IN angiogenesis_NNS ,_,

        normal_JJ vascular_NN development_NN has_VBZ been_VBN shown_VBN to_TO require_VB the_DT
        presence_NN of_IN the_DT CD_NNP 45_CD +_NN /_NN c-_NN Kit_NNP +_NN /_NN CD_NNP 34_CD +_NN hematopoietic_JJ stem_NN
        cells_NNS [_NN 58_CD ]_NN ,_, which_WDT are_VBP similar_JJ and_CC may_MD be_VB related_VBN to_TO adult_NN
        CEP_NNP cells_NNS ._.
        It_PRP has_VBZ been_VBN reported_VBN that_IN CEP_NNP cells_NNS are_VBP able_JJ to_TO
        participate_VB in_IN new_JJ vessel_NN growth_NN in_IN a_DT variety_NN of_IN animal_NN
        models_NNS ,_, including_VBG the_DT rabbit_NN ischemic_JJ hind_NN limb_NN model_NN [_NN
        59_CD ]_NN ._. In_IN patients_NNS with_IN inoperable_JJ coronary_JJ disease_NN ,_,
        increased_VBN circulating_VBG VEGF-A_NNP resulting_VBG from_IN transfection_NN of_IN
        myocardium_NN with_IN VEGF_NNP 165_CD cDNA_NN led_VBN to_TO a_DT significant_JJ
        mobilization_NN of_IN CEP_NNP cells_NNS [_NN 31_CD ]_NN ._. Another_DT recent_JJ publication_NN
        has_VBZ shown_VBN that_IN granulocyte-colony_JJ stimulating_VBG factor_NN
        mobilized_VBD CD_NNP 34_CD +_NN cells_NNS ,_, including_VBG endothelial_NN cell_NN
        precursors_NNS with_IN phenotypic_JJ and_CC functional_JJ characteristics_NNS
        of_IN embryonic_JJ angioblasts_NNS [_NN 60_CD ]_NN ._. When_WRB injected_VBN into_IN rats_NNS
        with_IN experimental_JJ myocardial_NN infarction_NN ,_, these_DT CD_NNP 34_CD +_NN cells_NNS
        contributed_VBD to_TO new_JJ vessel_NN growth_NN ,_, which_WDT led_VBD to_TO decreased_VBD
        cardiomyocyte_NN apoptosis_NNS ,_, to_TO reduced_VBN remodeling_VBG ,_, and_CC to_TO
        improved_VBN cardiac_JJ function_NN ._.
        Further_RB studies_VBZ of_IN how_WRB CEP_NNP cells_NNS are_VBP released_VBN from_IN bone_NN
        marrow_NN and_CC to_TO what_WP extent_NN they_PRP participate_VBP in_IN postnatal_NN
        angiogenesis_NNS will_MD certainly_RB provide_VB valuable_JJ information_NN
        regarding_VBG the_DT therapeutic_JJ potential_NN of_IN CEP_NNP cells_NNS ._. The_DT
        possibility_NN of_IN using_VBG CEP_NNP cells_NNS ,_, both_DT alone_RB and_CC in_IN
        combination_NN with_IN different_JJ angiogenic_JJ growth_NN factors_NNS ,_,
        represents_VBZ a_DT promising_JJ means_NNS of_IN obtaining_VBG stable_JJ vessels_NNS ._.
        Finally_RB ,_, since_IN the_DT use_NN of_IN CEP_NNP cells_NNS would_MD allow_VB easy_JJ 
        ex_FW vivo_NN gene_NN transfer_NN ,_, combining_VBG
        growth_NN factor-induced_JJ therapeutic_JJ angiogenesis_NNS with_IN gene_NN
        therapy_NN delivered_VBN via_IN CEP_NNP should_MD also_RB be_VB a_DT promising_JJ
        approach_NN ._.
      
      
        Conclusion_NNP
        As_IN research_NN into_IN therapeutic_JJ angiogenesis_NNS progresses_VBZ ,_,
        new_JJ information_NN regarding_VBG the_DT control_NN of_IN vessel_NN remodeling_NN
        and_CC stability_NN will_MD be_VB incorporated_VBN into_IN treatment_NN
        strategies_NNS ._. Better_NNP designed_VBD studies_NNS and_CC clinical_JJ trials_NNS
        that_WDT consider_VBP the_DT issues_NNS discussed_VBN ,_, coupled_VBN with_IN
        well-defined_JJ and_CC quantitative_JJ endpoints_NNS ,_, will_MD facilitate_VB
        the_DT development_NN of_IN novel_NN and_CC effective_JJ therapeutic_JJ
        approaches_NNS for_IN ischemic_JJ diseases_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        ang_NN =_SYM angiopoietin_NN ;_: CEP_NNP =_SYM circulating_VBG endothelial_NN
        precursor_NN ;_: FGF_NNP =_SYM fibroblast_NN growth_NN factor_NN ;_: FGF-_NNP 1_CD =_SYM acidic_JJ
        fibroblast_NN growth_NN factor_NN ;_: FGF-_NNP 2_CD =_SYM basic_JJ fibroblast_NN growth_NN
        factor_NN ;_: HIF-_NNP 1_CD α_NN =_SYM hypoxia_NN inducible_JJ factor-_NN 1_CD alpha_NN ;_: SPECT_NNP =_SYM
        single_JJ photon_NN emission_NN computed_JJ tomography_NN ;_: VEGF_NNP =_SYM vascular_NN
        endothelial_NN growth_NN factor_NN ._.
      
    
  
